📋 Pep IQ provides independent reference information for educational purposes only. Nothing here constitutes medical advice or treatment recommendation. All compounds require individual assessment. Consult a qualified physician before considering any peptide protocol.
Autophagy Inducer Cell-Penetrating Peptide

Tat-Beclin-1

Tat-BECN1 · TB-1 · 18 aa Beclin 1 + HIV-Tat fusion · Levine Lab (UT Southwestern, Nature 2013)

"An 18 amino acid peptide from the autophagy protein Beclin 1, fused to the HIV-Tat cell-penetrating domain. Designed by Beth Levine's lab at UT Southwestern to induce autophagy selectively — by displacing GAPR-1 from Beclin 1, freeing the protein to initiate cellular self-cleaning. Effects shown across rodent heart, brain, muscle, liver, kidney and cancer models. No human trials. The Tat-D11 retro-inverso variant is the more potent successor in current research."

Type
24 aa fusion · 18 aa Beclin 1 + HIV-Tat domain
Mechanism
GAPR-1 displacement · Beclin 1 release · mTORC1-independent
Status
UK: not illegal to buy or possess · WADA: not specifically listed · US FDA: not approved · animal models only · no human trials · Tat-D11 / L11 are the optimised variants
Half-life
Short — Tat-conjugated peptide profile (minutes to hours)
Protocol summary
Research stage
Preclinical · animal models only
Standard dose
2 mg/kg IP (rodent) · 30–50 μM (cells)
Treatment duration
Days to weeks (model-dependent)
Research-stage
2 mg/kg IP rodent (standard) · up to 10 mg/kg IP (higher-dose work) · 10–50 μM in cell culture
All published dosing is preclinical · animal and in-vitro only
Community-reported
5–15 mg SubQ weekly or bi-weekly · autophagy cycles 2–4 weeks on, off-cycle to follow
Allometric scaling from rodent IP · biohacker self-experimentation · no human safety data
How we read the evidence
Substantial preclinical evidence across tissues and disease models · no human trials · academic-research dominant · D11 retro-inverso variant in continued development
Animal evidence

Substantial. Tat-Beclin-1 induces autophagy in rodent heart, skeletal muscle, pancreas, brain, spinal cord, eye, kidney, liver, lung, bone, articular cartilage, ovary and cancer tissue — with experimental validation across each. Zebrafish embryo work shows conserved effect. Disease models showing therapeutic effect include Huntington's disease, Parkinson's disease, Alzheimer's models, chikungunya and West Nile virus infection, sepsis, MASLD (high-fat-diet mouse model, 2024), urea cycle disorders, and several cancer types. The 2013 Nature paper (Shoji-Kawata et al., Levine lab) is the foundational reference. Published animal work reports no obvious toxicity at standard research doses.

Community & clinical practice

Biohacker and longevity-community use exists but is sparse compared with established research peptides. The typical community-reported protocol is 5–15 mg subcutaneous weekly or bi-weekly, run in short autophagy cycles (2–4 weeks on, then time off) rather than continuous use. The 5–15 mg human range comes from allometric scaling of the rodent IP standard — 2 mg/kg in mice maps to roughly 0.16 mg/kg human-equivalent, about 11 mg for a 70 kg adult; users start lower and titrate. The cycling rationale parallels rapamycin and spermidine use for autophagy: induce, recover, repeat. No converged protocol has emerged the way BPC-157's 250–500 mcg/day has — the user base is smaller and more technical, Tat-conjugated peptides need careful cold-chain handling and reconstitution, and the peptide is significantly more expensive than mainstream research peptides. Academic research use still dominates self-experimentation.

Human trial data

None published. No clinical trials registered on ClinicalTrials.gov, EU CTR or ISRCTN as of 2026. Beth Levine's lab developed the peptide as a therapeutic candidate but Beth Levine passed away in 2020; downstream translational work was taken up by Casma Therapeutics and various academic groups. No Phase 1 has begun.

Regulatory status

Research peptide. Commercially available from biotech vendors (Novus, Bio-Techne, custom synthesis houses) as research-grade material with Certificate of Analysis. Not approved by MHRA, FDA, EMA or any other regulator. Not WADA-listed. UK: possession not a criminal offence — research peptide trade operates within the Human Medicines Regulations 2012 framework for compounds not marketed for human use.

Convergence

Tat-Beclin-1 is one of the best-characterised autophagy-inducing peptides in preclinical research. The mechanism is well-defined (GAPR-1 displacement → Beclin 1 release → autophagy induction) and distinct from rapamycin's mTORC1 inhibition route. The breadth of tissue and disease models with positive signal is unusually wide. The translational gap is significant — no human dose has been established, no human safety data exists. Anyone using Tat-Beclin-1 in self-experimentation is operating on animal-model evidence alone, with the standard dose-extrapolation and species-difference caveats. The D11 retro-inverso variant is the optimised successor in current academic work.

Origin & What It Is

From an HIV trick, a peptide that triggers cellular self-cleaning

Tat-Beclin-1 came out of Beth Levine's lab at UT Southwestern, published in Nature in February 2013 (Shoji-Kawata et al.). Levine spent her career mapping autophagy — the cellular pathway that recycles damaged proteins, organelles and intracellular pathogens. The Beclin 1 protein is the central initiator of that pathway. The question her lab was working on: could you design a small peptide that selectively switches Beclin 1 "on" — and induce autophagy without the broad off-target effects of compounds like rapamycin?

The answer came from an unexpected place — viral biology. HIV's Nef protein is known to hijack Beclin 1 to suppress host autophagy (autophagy is one of the cell's antiviral defences). Levine's group identified the exact region of Beclin 1 that Nef binds to, isolated an 18-amino-acid fragment from that region, and fused it to the cell-penetrating domain of HIV-Tat. The result is a peptide that crosses the cell membrane and competes with the normal negative regulator GAPR-1 for Beclin 1 binding — freeing Beclin 1 to initiate autophagy.

Beth Levine passed away in 2020 after a long illness. Downstream translational work has been taken up by Casma Therapeutics and several academic groups; the original peptide has also been refined into shorter, more potent variants — Tat-D11 (D-amino acid retro-inverso configuration, more protease-resistant) and Tat-L11 (natural L-configuration), both 11-amino-acid versions. The original 24-aa Tat-Beclin-1 (often abbreviated Tat-BECN1 or TB-1 in the literature) remains the reference compound for most preclinical work.

Science & Mechanism

Selective autophagy induction — without touching mTOR

Mechanism — Four Steps

1
Cell penetration: The HIV-Tat protein transduction domain (an arginine-rich sequence) crosses the cell membrane through a poorly understood but well-documented endocytic / direct-translocation process, carrying the attached Beclin 1 fragment into the cytoplasm. This is the same strategy used for many other cell-penetrating peptide therapeutics.
2
GAPR-1 displacement: In resting cells, Beclin 1 is sequestered at the Golgi apparatus by the negative regulator GAPR-1 (also called GLIPR2). Tat-Beclin-1 competes with GAPR-1 for the same binding site on Beclin 1 — when the Tat-Beclin-1 peptide outcompetes GAPR-1, Beclin 1 is released from the Golgi.
3
Autophagosome nucleation: Free Beclin 1 joins the Class III PI3K complex (PI3K-C1) at the phagophore assembly site. This triggers the lipid kinase activity that initiates autophagosome formation — the double-membrane vesicle that engulfs cellular cargo destined for lysosomal degradation.
4
mTORC1-independent: This is the key differentiator from rapamycin. Rapamycin induces autophagy by inhibiting the nutrient-sensing kinase mTORC1, which has broad effects on protein synthesis, cell proliferation, immunity and metabolism. Tat-Beclin-1 acts downstream of nutrient sensing — autophagy induction without the rest of mTOR's pleiotropic effects. That selectivity is the central translational argument for the compound.

The mechanism has been validated across an unusually wide range of tissues. In vivo autophagy induction has been documented in rodent heart, skeletal muscle (vastus lateralis), pancreas, brain, spinal cord, eye, kidney, liver, lung, bone, articular cartilage, ovary, and tumour tissue. Zebrafish embryo work shows conserved effect across species. The breadth of effect makes sense given that autophagy is a fundamental cellular pathway — a peptide that triggers it cleanly should work wherever Beclin 1 is expressed, which is essentially every cell type.

The selectivity argument has limits worth knowing. Tat-Beclin-1 doesn't only act through Beclin 1 — the Tat domain itself has some independent cell biology, and the peptide can affect GAPR-1's other interactions. But the mTORC1-independent autophagy induction is the dominant effect at standard research doses, and the central reason the peptide remains an active area of academic study more than a decade after the original Nature paper.

How Tat-Beclin-1 sits against other autophagy inducers: Rapamycin / sirolimus — mTORC1 inhibitor, FDA-approved (immunosuppressant), broad off-target effects. Metformin — mild autophagy induction via AMPK, FDA-approved (T2D). Spermidine — dietary polyamine, modest autophagy induction, supplement-grade. Trehalose — autophagy via mTOR-independent mechanism, food-grade. Tat-Beclin-1 — most selective at the autophagy step itself, but only validated preclinically.

Benefits & Evidence to Date

What the preclinical data shows

🔄
Autophagy induction (mechanism)
Validated across 10+ rodent tissues plus zebrafish. LC3-II, ATG5-12 and Beclin 1 markers all elevated dose-dependently; p62 reduced. Cell-culture EC50 around 30–50 μM range. The mechanism endpoint itself is the strongest data point.
● Strong — Mechanism validated across tissues
🧠
Neurodegeneration models
Effects shown in Huntington's, Parkinson's and Alzheimer's mouse models — autophagy clears the misfolded protein aggregates that drive these diseases. Behavioural and histological improvements in the published animal work. No human translation yet.
● Moderate — Multiple animal models, no human data
🦠
Antiviral activity
Tat-Beclin-1 improves outcomes in chikungunya virus and West Nile virus mouse models. Mechanism: autophagy directly clears intracellular viral particles (xenophagy). Conceptually broad-spectrum but only validated for a small number of viruses preclinically.
● Moderate — Specific virus models in animals
🫀
Hepatic / MASLD
2024 paper (Chen et al., IJMS): high-fat-diet mouse model treated intraperitoneally with TB-1 showed reduced liver fat, improved histopathology, normalised serum biochemistry. Autophagy markers elevated dose- and time-dependently in HepG2 cell line. Single study; not replicated yet.
● Limited — Single recent animal study
🧬
Cancer (context-dependent)
Autophagy is double-edged in cancer — early-stage tumours may be suppressed by autophagy (clearing damaged cells), but established tumours often use autophagy for survival under metabolic stress. Tat-Beclin-1 has shown anti-tumour effects in some preclinical models and pro-survival effects in others. Context-dependent and the area requiring most caution.
● Limited — Context-dependent, mixed signal
Safety to Date

Safety profile — animal data only, theoretical considerations apply

⚠️
All safety information is from animal models. No human safety data exists. Published animal work reports no obvious toxicity at standard research doses, and the urea-cycle-disorder and MASLD studies specifically describe TB-1 as well-tolerated in their mouse cohorts. That is not the same as a human safety profile. Anyone using Tat-Beclin-1 in self-experimentation is doing so without published human dose-finding, tolerability or long-term safety data.
Unknown
No human safety data — no Phase 1 trial has been conducted. No published human dose, no human tolerability data, no long-term human safety. Animal-model "no obvious toxicity" doesn't translate directly.
Moderate
Cancer — context-dependent — autophagy supports established tumour survival under metabolic stress in some cancers. Inducing autophagy systemically in someone with an undiagnosed cancer could theoretically support tumour persistence. The signal is context-dependent in animal models and the area requiring most caution.
Unknown
Chronic autophagy induction — what continuous Beclin 1 activation does over months or years isn't known. Animal work uses short courses (days to weeks). Excessive autophagy can cause autophagic cell death; the threshold in humans isn't characterised.
Mild
Reconstitution and handling — Tat-conjugated peptides are sensitive to oxidation and aggregation. Standard cold-chain storage and careful reconstitution matter more than for simpler research peptides.
Unknown
Product variation — vendors sell several forms (original Tat-Beclin-1 24 aa, Tat-D11, Tat-L11, and L11S scrambled control). Identity and potency vary; published research uses specific reference standards (Novus, custom synthesis) that may not match what's sold elsewhere.